Last reviewed · How we verify

Low Molecular Weight Heparin

Yangzhou University · FDA-approved active Small molecule Quality 5/100

Low Molecular Weight Heparin is a Small molecule drug developed by Yangzhou University. It is currently FDA-approved. Also known as: Fraxiparine, tinzaparin, Innohep LEO pharmaceutical products, heparin.

At a glance

Generic nameLow Molecular Weight Heparin
Also known asFraxiparine, tinzaparin, Innohep LEO pharmaceutical products, heparin, Nadroparin calcium
SponsorYangzhou University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Low Molecular Weight Heparin

What is Low Molecular Weight Heparin?

Low Molecular Weight Heparin is a Small molecule drug developed by Yangzhou University.

Who makes Low Molecular Weight Heparin?

Low Molecular Weight Heparin is developed and marketed by Yangzhou University (see full Yangzhou University pipeline at /company/yangzhou-university).

Is Low Molecular Weight Heparin also known as anything else?

Low Molecular Weight Heparin is also known as Fraxiparine, tinzaparin, Innohep LEO pharmaceutical products, heparin, Nadroparin calcium.

What development phase is Low Molecular Weight Heparin in?

Low Molecular Weight Heparin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing